Cyclophosphamide (CYC) can control diffuse proliferative lupus nephritis (DPLN) by potent immunosuppression but remains associated with serious and life-threatening complications. Drugs that specifically target mediators of DPLN may help to reduce CYC dose and side effects. Monocyte chemoattractant protein (MCP-1)/CCL2 mediates monocyte and T cell recruitment in DPLN and Ccl2-specific L-enantiomeric RNA Spiegelmer mNOX-E36 neutralizes the biological effects of murine Ccl2 in vitro and in vivo. We injected MRL lpr/lpr mice with DPLN from 14 weeks of age with vehicle, weekly 30 mg/kg CYC (full dose), monthly 30 mg/kg CYC (one-fourth full dose), pegylated control Spiegelmer, pegylated anti-Ccl2 Spiegelmer (3/week), pegylated anti-Ccl2 Spiegelmer plus CYC one-fourth full dose and mycophenolate mofetil. At week 24, DPLN and autoimmune lung injury were virtually abolished with CYC full dose but not with CYC onefourth full dose. The CYC one-fourth full dose/Spiegelmer combination was equipotent to CYC full dose on kidney and lung injury. CD3 ϩ CD4 Ϫ CD8 Ϫ and CD3 ϩ CD4 ϩ CD25 ϩ T cells and serum interleukin-12p40 and tumor necrosis factor-␣ levels were all markedly affected by CYC full dose but not by CYC one-fourth full dose. No additive effects of anti-Ccl2 Spiegelmer were noted on bone marrow colony-forming unitgranulocyte macrophage counts and 7/4 high monocyte counts, lymphoproliferation, and spleen T cell depletion. In summary, anti-Ccl2 Spiegelmer permits 75% dose reduction of CYC for controlling DPLN and pneumonitis in MRL-Fas(lpr) mice, sparing suppressive effects of full-dose CYC on myelosuppression and T cell depletion. We propose anti-Ccl2 Spiegelmer therapy as a novel strategy to reduce CYC toxicity in the treatment of severe lupus.
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Control of human diffuse proliferative lupus nephritis (DPLN) requires potent immunosuppression with either cyclophosphamide (CYC) or mycophenolate mofetil (MMF).
Each of the two drugs is associated with significant morbity and mortality. For example, in the Aspreva Lupus Management Study trial, MMF caused serious adverse effects in 27.7% and treatment-related death in 4.9% and CYC in 22.8 and 2.8% of treated patients, respectively (Appel et al., 2007) .
Most serious adverse effects and deaths were related to infections because of the unspecific immunosuppressive effects of CYC and MMF (Appel et al., 2007) . Novel drugs specifically blocking autoimmune inflammation may allow the reduction of the toxicity of current treatment protocols either by replacing CYC and MMF or by allowing significant dose reductions when used in combination.
Cytokine antagonism is a powerful strategy to prevent tissue damage in chronic inflammation (Steinman, 2004) . Beyond cytokines and interleukins, CC-chemokines represent potential targets for specific antagonism because CCchemokines mediate immune cell activation and their recruitment to sites of inflammation (Baggiolini, 1998; Luster et al., 2005) . Experimental studies revealed that Ccl2, formerly known as monocyte-chemoattractant protein-1, and its chemokine receptor, Ccr2, have crucial roles in autoimmune tissue injury, such as the manifestations of systemic lupus erythematosus (SLE) (Gerard and Rollins, 2001) . Ccl2-or Ccr2-deficient MRL lpr/lpr mice with experimental SLE are protected from DPLN (Tesch et al., 1999; Pérez de Lema et al., 2005) . Based on these studies, several groups have tried to block Ccl2 or Ccr2 with suitable antagonists in mice with experimental SLE. One example is a truncated Ccl2 that exerts inhibitory function. Expressed in situ by delayed gene therapy or transfer of transfected cells, the truncated Ccl2 markedly reduced autoimmune tissue injury in MRL lpr/lpr mice (Hasegawa et al., 2003; Shimizu et al., 2004) . However, such experimental approaches validate the Ccl2/Ccr2 axis as a target rather than representing applicable therapeutics in humans. Gene transfer causes irrepressible antagonist production, and local tumors complicated the transplantation of transfected cells (Hasegawa et al., 2003; Shimizu et al., 2004) .
We have recently proposed an alternative strategy to block Ccl2, i.e., with a Ccl2-binding mirror-image RNA oligonucleotide, a so-called Spiegelmer. Spiegelmers represent a new class of nuclease-resistant RNA aptamers that can bind and inhibit target molecules conceptually similar to monoclonal antibodies (Eulberg and Klussmann, 2003) . The mirrorimage configuration of the ribonucleotides prevents Spiegelmer digestion by nucleases (Klussmann et al., 1996) . Hence, Spiegelmers are very well suited for in vitro and in vivo applications (Wlotzka et al., 2002; Helmling et al., 2004; Denekas et al., 2006; Purschke et al., 2006) . We previously reported the design of anti-Ccl2 Spiegelmer (mNOX-E36), a Spiegelmer that potently neutralizes the biological functions of murine Ccl2 in vitro and in vivo (Kulkarni et al., 2007) . In cell-based assays employed with THP-1 cells, Ccl2-mediated chemotaxis and a Ca 2ϩ release could be inhibited, with the anti-Ccl2 Spiegelmer displaying half-maximal efficacy in the low single-digit nanomolar range. In vivo studies with antiCcl2 Spiegelmer were carried out in female MRL lpr/lpr mice. Ccl2 blockade with the anti-Ccl2 Spiegelmer for 10 weeks starting at an age of 14 weeks significantly improved DPLN (Kulkarni et al., 2007) . Although the therapeutic effect was clearly evident, it remained unclear how the efficacy of the anti-Ccl2 Spiegelmer would compare with that of CYC or MMF. Based on the specific anti-inflammatory mechanism of Ccl2 blockade, we assumed that treatment with an anti-Ccl2 Spiegelmer would not be as effective as CYC full dose for the treatment of DPLN. However, we hypothesized that therapeutic effects equivalent to CYC full dose might be achieved with a combination of less frequent CYC dosing plus antiCcl2 Spiegelmer, which may avoid the toxicity of CYC full dose.
Materials and Methods
Preparation of Anti-Ccl2 Spiegelmer mNOX-E36. The identification and molecular structure of the anti-Ccl2 Spiegelmer mNOX-E36 have been described previously in detail (Kulkarni et al., 2007) . In brief, mNOX-E36 (5Ј-GGCGACAUUG GUUGGG CAUG AGGCGAGGCC CUUUGAUGAA UCCGCGGCCA-3Ј) and the control Spiegelmer revm-NOX-E36 (5Ј-ACCGGCGCCU AAGUAGUUUC CCGGAGCGGA GUACGGGUUG GUUACAGCGG-3Ј) were synthesized using standard phosphoramidite chemistry. Spiegelmers were modified with a 40-kDa polyethylene glycol moiety at the 3Ј terminus. (combination) , and 100 mg/kg/day MMF orally (Roche Diagnostics, Mannheim, Germany). All vehicle and Spiegelmer injections were given 3ϫ/week. Plasma levels of mNOX-E36 were determined in samples obtained from the retro-orbital sinus 24 h after injection from Spiegelmer-treated groups on weeks 1, 3, 7, and 10 of treatment. Spiegelmer plasma levels were determined as described previously (Drolet et al., 2000) . Blood samples were drawn under isoflurane anesthesia and urine was collected on week 24 from each of the survived mice for further plasma and urine analysis. Mice were sacrificed by cervical dislocation at the end of week 24 of age. All experimental procedures were performed according to the German animal care and ethics legislation and were approved by the local government authorities.
Evaluation of Systemic Lupus. The weight ratio of spleen and the bulk of mesenterial lymph nodes to total body weight were calculated as markers of the lupus-associated lymphoproliferative syndrome. Urine albumin/creatinine ratio was determined as described previously (Pawar et al., 2006) . Plasma IL-12p40 and TNF-␣ levels were analyzed by ELISA (TNF-␣, BioLegend, San Diego, CA; IL-12p40, BD-Pharmingen, San Diego, CA). From all mice, kidneys and lungs were fixed in 10% buffered formalin, processed, and embedded in paraffin. Fivemicrometer sections for periodic acid-Schiff stain were prepared following routine protocols (Anders et al., 2002) . The severity of the renal lesions was graded using the indices for activity and chronicity as described for human lupus nephritis (Austin et al., 1984) . The severity of the peribronchial inflammation was graded semiquantitatively from 0 to 3 by a blinded observer. Immunostaining was performed as described previously (Anders et al., 2002) . The following primary antibodies were used: rat anti-Mac2 (macrophages; CEDARLANE Laboratories Ltd., Burlington, ON, Canada; 1:50) and anti-mouse CD3 (1:100, clone 500A2, BD-Pharmingen). Negative controls included incubation with a respective isotype antibody. Positive glomerular cells were counted in 15 cortical glomeruli per section. Interstitial cells were counted by a high-power field. Urinary albumin was assessed by ELISA (Bethyl Laboratories, Montgomery, TX), and urinary creatinine concentrations were determined using an automatic AutoAnalyzer (Integra 800; Roche Diagnostics).
Evaluation of Monocytopenia and Bone Marrow Colony Forming Unit-Granulocyte Macrophage Counts. To evaluate therapy induced monocytopenia and myelotoxicity, we treated four groups of mice (n ϭ 5) as follows: 5% glucose s.c., 50 mg/kg/3ϫ/week anti-Ccl2 Spiegelmer s.c., CYC full dose i.p., and combination of CYC one-fourth full dose i.p. and 50 mg/kg/3ϫ/week anti-Ccl2 Spiegelmer s.c. for 4 weeks. After 4 weeks of treatment, blood was drawn from the retro-orbital plexus under isoflurane anesthesia. Mice were sacrificed to get the bone marrow cells. After counting, 3 ϫ 10 4 bone marrow cells derived from each group were cultured with Methocult media (M3132; Stem Cell Technologies, Vancouver, BC, Canada) supplemented with murine granulocyte macrophage-colony-stimulating factor (10 ng/ml) for colony-forming unit (CFU)-granulocyte macrophage (GM) assay as per the instructions in the kit insert. CFU-GM colonies were counted on day 12.
Flow Cytometry. Flow cytometry was performed using a FACScalibur machine and the previously described method for monocyte subsets analysis (Tsou et al., 2007) . Blood samples and bone marrow samples were incubated with rat anti-mouse CD16/CD32 (1:500 or 1 g/ml; BD Biosciences, San Jose, CA) for 30 min to block Fc recep-tors. Blood samples were incubated for 1 h at 4°C with fluorescently labeled antibodies: Ly-6G-FITC (2.8 g/ml; BD Biosciences), 7/4-PE (1:10; Serotec, Oxford, UK). Autoreactive T cells and regulatory T cells were identified, from single-cell spleenocytes suspension, by staining with anti-mouse CD3-FITC, anti-mouse CD45-PE, antimouse CD4-APC, anti-mouse CD8-PerCp, and anti-mouse CD25-PerCp (all from BD Pharmingen). Cell density in every spleen cell single cell suspension sample was analyzed by using counting beads (Invitrogen, Carlsbad, CA).
Statistical Analysis. Data were expressed as mean Ϯ S.E.M. Comparison between groups were performed using univariate ANOVA and unpaired Student's t test. Post hoc Bonferroni's correction was used for multiple comparisons. A value of p Ͻ 0.05 was considered to indicate statistical significance.
Results

Pharmacokinetics of Spiegelmer Plasma Levels in MRL
lpr/lpr Mice. To monitor drug exposure in MRL lpr/lpr mice, mNOX-E36 plasma levels were determined in weeks 1, 3, 6, and 10 treatment, i.e., the weeks 15, 18, 21, and 24 of age. Twenty-four hours after administration of 50 mg/kg mNOX-E36, mean plasma levels were approximately 1 M throughout the study in both of the Spiegelmer-treated groups (Fig. 1A) . The progressive kidney disease of MRL lpr/lpr mice apparently did not modulate Spiegelmer pharmacokinetics, and neither drug accumulation nor metabolic induction or reduction was detected. Exposure to mNOX-E36 was associated with an increase of serum Ccl2 levels in MRL lpr/lpr mice, which was not observed in MRL lpr/lpr mice treated with the control Spiegelmer (Fig. 1B) . Thus, upon s.c. administration to MRL lpr/lpr mice, pharmacologically relevant levels of circulating anti-Ccl2 Spiegelmer, most probably, bind and retain Ccl2 in the circulation.
Add-on Therapy with Anti-Ccl2 Spiegelmers Improves the Effects of CYC One-Fourth Full Dose on Kidney Disease of MRL lpr/lpr Mice. Female MRL lpr/lpr mice develop proliferative immune complex glomerulonephritis similar to DPLN in humans. We treated MRL lpr/lpr mice with CYC, MMF, Spiegelmer, or vehicle from weeks 14 to 24 of age. This represents a therapeutic treatment protocol because at 14 weeks of age, MRL lpr/lpr mice showed DPLN with an activity score index of 4.1 Ϯ 1.1. At this age, major abnormalities of the tubulointerstitial compartment were absent (data not shown). After 10 weeks of treatment, vehicle-and control Spiegelmer-treated MRL lpr/lpr mice revealed DPLN associated with glomerular hypercellularity, expansion of glomerular matrix, focal tuft necrosis, and a mixed periglomerular and interstitial inflammatory cell infiltrate (Fig. 2) . CYC full dose and CYC one-fourth full dose plus anti-Ccl2 Spiegelmer were equally potent in improving the activity and chronicity index of lupus nephritis (Figs. 2  and 3) . Furthermore, CYC full dose-treated mice showed 100% survival, and survival rates of CYC one-fourth full dose plus anti-Ccl2 Spiegelmer-treated MRL lpr/lpr mice did not significantly differ from those of CYC full-dose-treated MRL lpr/lpr mice. Proteinuria as assessed by urinary albumin/creatinine ratios trended lower in these groups compared with vehicle treatment, but this did not reach statistical significance (data not shown). Anti-Ccl2 Spiegelmer and CYC one-fourth full dose alone and MMF were less potent but still significantly improved the activity and chronicity indices of lupus nephritis (Figs. 2  and 3) . Thus, adding anti-Ccl2 Spiegelmer to a CYC one-fourth full dose-based regimen is as potent as CYC full-dose therapy for DPLN of MRL lpr/lpr mice. Anti-Ccl2 Spiegelmer and CYC One-Fourth Full Dose Have Additive Effects on the Reduction of Immune Cell Infiltrates in Kidneys of MRL lpr/lpr Mice. Immune cell infiltrates contribute to renal damage in lupus nephritis (Vielhauer and Anders, 2006) , and Ccl2 mediates the recruitment of T cells and macrophages to MRL lpr/lpr mice (Tesch et al., 1999) . Therefore, we hypothesized that the additive effects of an anti-Ccl2 Spiegelmer/CYC one-fourth full dose combination may relate to impaired macrophage and T cell recruitment in MRL lpr/lpr mice. We performed immunostaining for Mac2-positive macrophages and CD3-positive T cells and assessed the number of glomerular and interstitial macrophages and interstitial T cells. The numbers of glomerular T cells were not analyzed because they were very low in all groups. CYC full dose and CYC one-fourth full dose plus anti-Ccl2 Spiegelmer were equally potent in reducing the numbers of glomerular and interstitial Mac2-positive macrophages in kidneys of MRL lpr/lpr mice (Fig. 3, C and D) . AntiCcl2 Spiegelmer and CYC one-fourth full dose alone and MMF were less potent but still significantly reduced the macrophages in both compartments (Fig. 3, C and D) . The Spiegelmer in female MRL lpr/lpr mice during the course of treatment from 15 to 24 weeks of age. Plasma sampling was carried out 24 h after the first weekly injection for anti-Ccl2 Spiegelmer on weeks 15, 18, 21, and 24 of age. The Spiegelmer plasma levels were determined by a modification of a sandwich hybridization procedure as described under Materials and Methods. Data are expressed as means Ϯ S.D. of seven to 12 mice in each group. B, plasma Ccl2 levels were determined in mice of all groups at the end of the study. Data are expressed as means Ϯ S.E.M. of seven to 12 mice in each group. ‫,ءءء‬ p Ͻ 0.001 versus control.
Anti-Ccl2 Spiegelmers in Lupus Nephritis
373
at ASPET Journals on November 4, 2017 jpet.aspetjournals.org Downloaded from same was found for the numbers of interstitial CD3 positive T cells (Fig. 3E) . Thus, the additive effect of anti-Ccl2 Spiegelmer and CYC one-fourth full dose on renal pathology of MRL lpr/lpr mice is associated with a significant reduction of interstitial macrophages and T cells and of glomerular macrophages, which was similar to the effect of CYC full dose.
Anti-Ccl2 Spiegelmer and CYC One-Fourth Full Dose Have Additive Effects on the Reduction of Lung Injury in MRL
lpr/lpr Mice. Autoimmune peribronchitis is another manifestation of lupus-like systemic autoimmunity in MR-L lpr/lpr mice. CYC full dose was more effective than CYC one-fourth full dose in controlling lung injury in MRL lpr/lpr mice. However, CYC one-fourth full dose plus anti-Ccl2 Spiegelmer were as effective as CYC full dose (Fig. 4) . It is surprising that MMF had no effect of lung injury in MRL lpr/lpr mice. Thus, the CYC one-fourth full dose/Spiegelmer combination was as effective as CYC full dose on autoimmune lung injury in MRL lpr/lpr mice. Anti-Ccl2 Spiegelmer/CYC One-Fourth Full Dose Combination and T Cell Depletion in MRL lpr/lpr Mice. Systemic autoimmunity of MRL lpr/lpr mice is characterized by lymphoproliferation evident from massive splenomegaly and bulks of cervical, axillary, inguinal, and mesenterial lymph nodes (Cohen and Eisenberg, 1991) . CYC treatment caused a dosedependent reduction of spleen and lymph node weights in 24-week-old MRL lpr/lpr mice compared with vehicle-treated MRL lpr/lpr mice (Fig. 5, A and B) . The effect of MMF treatment was less evident and only affected lymph node weights. AntiCcl2 Spiegelmer itself had no significant effect on the weight of spleens and lymph nodes in MRL lpr/lpr mice. Furthermore, antiCcl2 Spiegelmer had no effect on the serum levels of IL-12p40 or TNF-␣, two cytokines that regulate T cell and monocyte function in autoimmunity and antimicrobial host defense (Fig. 5, C  and D) . In contrast, serum IL-12p40 and TNF-␣ levels were markedly decreased in MRL lpr/lpr mice treated with CYC full dose (Fig. 5, C and D) . In a separate experiment, groups of MRL lpr/lpr mice were treated with vehicle, anti-Ccl2 Spiegelmer, CYC one-fourth full dose plus anti-Ccl2 Spiegelmer, or CYC full dose from 8 to 12 weeks of age to characterize immune cell subsets in spleens, bone marrows, and peripheral blood by flow cytometry. CYC full dose but not CYC one-fourth full dose plus anti-Ccl2 Spiegelmer significantly reduced the number of spleen cells (Fig. 6A) . This was consistent for all spleen T cell subsets studied, i.e., CD3 (Fig. 6B) . Together, anti-Ccl2 Spiegelmer and CYC one-fourth full dose had no additive effects on T cell depletion as seen with CYC full dose in MRL lpr/lpr mice.
Anti-Ccl2 Spiegelmer/CYC One-Fourth Full Dose Combination and Myelosuppression in MRL lpr/lpr Mice. A full dose of CYC usually causes transient myelosuppression, which renders patients susceptible to life-threatening infections. Therefore, we evaluated markers of myelosuppression in treated MRL lpr/lpr mice for 4 weeks to have a single CYC injection in the combination group and four weekly injections in the CYC full-dose group. Spiegelmer and vehicle-treated groups received injections 3ϫ/week. CYC full dose significantly reduced the numbers of 7/4 bri monocytes in bone marrows of MRL lpr/lpr mice, whereas anti-Ccl2 Spiegelmertreated and CYC one-fourth full dose plus anti-Ccl2 Spiegelmer-treated MRL lpr/lpr mice had elevated numbers of 7/4 bri bone marrow monocytes (Fig. 6C) . Anti-Ccl2 Spiegelmer-and CYC-treated MRL lpr/lpr mice showed a trend toward lower 7/4 high monocyte counts in peripheral blood, but this did not reach statistical significance for any of the groups (Fig. 6D) . The CFU-GM colony assay in Methocult media supplemented with rm-GM-CSF is a test for myelosuppression, i.e., the growing capacity of hematopoietic stem cells and immune cell progenitors. CFU-GM colonies in CYC full dose-treated MRL lpr/lpr mice were significantly reduced compared with vehicle, whereas anti-Ccl2 Spiegelmer and CYC one-fourth full dose/Spiegelmer treatment did not effect CFU-GM counts (Fig. 6E) . Together, the combination of antiCcl2 Spiegelmer and CYC one-fourth full dose does not cause myelosuppression as seen with CYC full dose in MRL lpr/lpr mice.
Discussion
The immunosuppressive treatment regimen for DPLN involving high-dose CYC or MMF remains associated with serious and even potential life-threatening complications, i.e., infections (Katsifis and Tzioufas, 2004; Appel et al., 2007) . Thus, combinations of CYC with drugs that more specifically interact with autoimmune tissue injury in lupus may overcome this clinical problem.
Our data demonstrate that a combination of the anti-Ccl2 Spiegelmer mNOX-E36 and less frequent CYC full dose treatment initiated at 14 weeks of age, a time point when autoimmune tissue injury is already established (Tesch et al., 1999; Pérez de Lema et al., 2001) , is as effective as CYC full dose in suppressing DPLN and lung injury in MRL lpr/lpr mice. It is interesting that the effect of mNOX-E36, either given alone or in combination with CYC one-fourth full dose, had no additive effects on T cell depletion, serum TNF-␣ and IL-12p40 levels, and myelosuppression. All these parameters were severely suppressed by a CYC full dose, which we show and was shown previously by others to effectively control DPLN in experimental models of SLE including MRL lpr/lpr mice (Casey, 1968; Gelfand et al., 1972; Shiraki et al., 1984; Smith et al., 1984; Jonsson et al., 1999) . Apparently, antiCcl2 Spiegelmer has no antiproliferative effect on immune cells and bone marrow-derived blood cell progenitors as the alkylating agent CYC. In contrast, the anti-Ccl2 Spiegelmer increased the numbers of bone marrow macrophages, most probably by blocking the role of Ccl2 for monocyte evasion from the bone marrow (Serbina and Pamer, 2006; Kulkarni et al., 2007) . As a consequence, anti-Ccl2 Spiegelmer does not affect the underlying autoimmune dysregulation of MRL lpr/lpr mice. As we have shown previously, anti-Ccl2- mice from all groups. E, to assess drug-induced myelosuppression, bone marrows were cultured to quantify CFU-GM counts of hematopoietic progenitors as described under Materials and Methods. Data represent mean percentages Ϯ S.E.M. AntiCcl2 Sp, pegylated anti-Ccl2 Spiegelmer (mNOX-E36); CYC (1/4)th, monthly 30 mg/kg cyclophosphamide; CYC full, weekly 30 mg/kg cyclophosphamide. ‫,ء‬ p Ͻ 0.05 versus vehicle; #, p Ͻ 0.05 versus CYC one-fourth dose/anti-Ccl2 Spiegelmer combination; N.S., not significant. Spiegelmer does not affect the production of DNA autoantibodies by autoreactive B cells in MRL lpr/lpr mice (Kulkarni et al., 2007) . In the present study, we show that anti-Ccl2 Spiegelmer does not modulate the CD4/CD8 double-negative "autoreactive" T cell population. These data are consistent with data from other groups showing that Ccl2 blockade does not modulate the autoimmune process in itself but rather the local mechanisms of autoimmune tissue injury (Tesch et al., 1999; Hasegawa et al., 2003; Shimizu et al., 2004) . This would argue against additive unspecific effects of a Spiegelmer-CYC combination on complications that relate to general immunosuppression, i.e., infections, which, however, was not obvious in our experimental setting. Rather, we observed an additive effect of the anti-Ccl2 Spiegelmer and less frequent CYC full dose on the numbers of renal macrophages and T cells, which is consistent with the role of Ccl2 for renal macrophage and T cell recruitment (Tesch et al., 1999; Hasegawa et al., 2003; Shimizu et al., 2004) . Given the established role of macrophages and T cell infiltrates for renal damage, we propose that specific blockade Ccl2-dependent renal macrophage and T cell recruitment prevented glomerular and tubulointerstitial damage in MRL lpr/lpr mice. However, late-onset treatment with anti-Ccl2 Spiegelmer alone was not as effective as high-dose CYC on autoimmune tissue injury in MRL lpr/lpr mice. Higher doses of the anti-Ccl2 Spiegelmer might be more potent as the dose tested here but other than Ccl2-dependent renal macrophage and T cell recruitment contribute to autoimmune renal injury in DPLN. Hence, Spiegelmer monotherapy is unlikely to be superior to CYC full dose for the treatment of DPLN.
In conclusion, inhibition of Ccl2 in combination with CYC allows significant reduction in dosing frequency of CYC, which avoids unwarranted T cell depletion and myelosuppression despite equipotent control of autoimmune tissue damage like DPLN. This novel concept may help to reduce the serious and potentially life-threatening CYC toxicity in patients with DPLN and potentially other serious manifestations of autoimmune disease that involve Ccl2-dependent immune cell infiltrates.
